Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 205

1.

Development and external validation study of a melanoma risk prediction model incorporating clinically assessed naevi and solar lentigines.

Vuong K, Armstrong BK, Drummond M, Hopper JL, Barrett JH, Davies JR, Bishop DT, Newton-Bishop J, Aitken JF, Giles GG, Schmid H, Jenkins MA, Mann GJ, McGeechan K, Cust AE.

Br J Dermatol. 2019 Aug 4. doi: 10.1111/bjd.18411. [Epub ahead of print]

PMID:
31378928
2.

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets.

Newell F, Kong Y, Wilmott JS, Johansson PA, Ferguson PM, Cui C, Li Z, Kazakoff SH, Burke H, Dodds TJ, Patch AM, Nones K, Tembe V, Shang P, van der Weyden L, Wong K, Holmes O, Lo S, Leonard C, Wood S, Xu Q, Rawson RV, Mukhopadhyay P, Dummer R, Levesque MP, Jönsson G, Wang X, Yeh I, Wu H, Joseph N, Bastian BC, Long GV, Spillane AJ, Shannon KF, Thompson JF, Saw RPM, Adams DJ, Si L, Pearson JV, Hayward NK, Waddell N, Mann GJ, Guo J, Scolyer RA.

Nat Commun. 2019 Jul 18;10(1):3163. doi: 10.1038/s41467-019-11107-x.

3.

Data Independent Acquisition Proteomic Analysis Can Discriminate between Actinic Keratosis, Bowen's Disease, and Cutaneous Squamous Cell Carcinoma.

Azimi A, Yang P, Ali M, Howard V, Mann GJ, Kaufman KL, Fernandez-Penas P.

J Invest Dermatol. 2019 Jun 27. pii: S0022-202X(19)31794-4. doi: 10.1016/j.jid.2019.06.128. [Epub ahead of print]

PMID:
31254517
4.

Cost-Effectiveness of a Psycho-Educational Intervention Targeting Fear of Cancer Recurrence in People Treated for Early-Stage Melanoma.

Dieng M, Khanna N, Kasparian NA, Costa DSJ, Butow PN, Menzies SW, Mann GJ, Cust AE, Morton RL.

Appl Health Econ Health Policy. 2019 Oct;17(5):669-681. doi: 10.1007/s40258-019-00483-6.

PMID:
31228015
5.

Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure.

Cust AE, Drummond M, Bishop DT, Azizi L, Schmid H, Jenkins MA, Hopper JL, Armstrong BK, Aitken JF, Kefford RF, Giles GG, Demenais F, Goldstein AM, Barrett JH, Kanetsky PA, Elder DE, Mann GJ, Newton-Bishop JA.

J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1874-1885. doi: 10.1111/jdv.15680. Epub 2019 Jun 7.

6.

Melanoma Explorer: a web application to allow easy reanalysis of publicly available and clinically annotated melanoma omics data sets.

Strbenac D, Wang K, Wang X, Dong J, Mann GJ, Mueller S, Yang JYH.

Melanoma Res. 2019 Jun;29(3):342-344. doi: 10.1097/CMR.0000000000000533.

PMID:
31026248
7.

Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12-month follow-up results of a randomized controlled trial.

Dieng M, Morton RL, Costa DSJ, Butow PN, Menzies SW, Lo S, Mann GJ, Cust AE, Kasparian NA.

Br J Dermatol. 2019 Apr 9. doi: 10.1111/bjd.17990. [Epub ahead of print]

PMID:
30965384
8.

Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas.

Quek C, Rawson RV, Ferguson PM, Shang P, Silva I, Saw RPM, Shannon K, Thompson JF, Hayward NK, Long GV, Mann GJ, Scolyer RA, Wilmott JS.

Oncotarget. 2019 Jan 29;10(9):930-941. doi: 10.18632/oncotarget.26584. eCollection 2019 Jan 29.

9.

Molecular Genomic Profiling of Melanocytic Nevi.

Colebatch AJ, Ferguson P, Newell F, Kazakoff SH, Witkowski T, Dobrovic A, Johansson PA, Saw RPM, Stretch JR, McArthur GA, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Waddell N, Scolyer RA, Wilmott JS.

J Invest Dermatol. 2019 Aug;139(8):1762-1768. doi: 10.1016/j.jid.2018.12.033. Epub 2019 Feb 14.

PMID:
30772300
10.

Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT.

Taylor NJ, Mitra N, Qian L, Avril MF, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cuellar F, Cust AE, Demenais F, Elder DE, Gerdes AM, Ghiorzo P, Goldstein AM, Grazziotin TC, Gruis NA, Hansson J, Harland M, Hayward NK, Hocevar M, Höiom V, Holland EA, Ingvar C, Landi MT, Landman G, Larre-Borges A, Mann GJ, Nagore E, Olsson H, Palmer JM, Perić B, Pjanova D, Pritchard AL, Puig S, Schmid H, van der Stoep N, Tucker MA, Wadt KAW, Yang XR, Newton-Bishop JA, Kanetsky PA; GenoMEL Study Group.

J Am Acad Dermatol. 2019 Aug;81(2):386-394. doi: 10.1016/j.jaad.2019.01.079. Epub 2019 Feb 5.

PMID:
30731170
11.

The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma.

Zhao X, Little P, Hoyle AP, Pegna GJ, Hayward MC, Ivanova A, Parker JS, Marron DL, Soloway MG, Jo H, Salazar AH, Papakonstantinou MP, Bouchard DM, Jefferys SR, Hoadley KA, Ollila DW, Frank JS, Thomas NE, Googe PB, Ezzell AJ, Collichio FA, Lee CB, Earp HS, Sharpless NE, Hugo W, Wilmott JS, Quek C, Waddell N, Johansson PA, Thompson JF, Hayward NK, Mann GJ, Lo RS, Johnson DB, Scolyer RA, Hayes DN, Moschos SJ.

Front Oncol. 2019 Jan 4;8:584. doi: 10.3389/fonc.2018.00584. eCollection 2018.

12.

RAB27A promotes melanoma cell invasion and metastasis via regulation of pro-invasive exosomes.

Guo D, Lui GYL, Lai SL, Wilmott JS, Tikoo S, Jackett LA, Quek C, Brown DL, Sharp DM, Kwan RYQ, Chacon D, Wong JH, Beck D, van Geldermalsen M, Holst J, Thompson JF, Mann GJ, Scolyer RA, Stow JL, Weninger W, Haass NK, Beaumont KA.

Int J Cancer. 2019 Jun 15;144(12):3070-3085. doi: 10.1002/ijc.32064. Epub 2019 Jan 3.

PMID:
30556600
13.

The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Population-based data on diagnosis and management.

Guitera P, Collgros H, Madronio CM, Goumas C, Mann GJ, Watts CG, Pereira AR, Armstrong BK, Drummond M, Morton RL, Scolyer RA, Menzies SW, Thompson JF, Cust AE.

Australas J Dermatol. 2019 May;60(2):118-125. doi: 10.1111/ajd.12928. Epub 2018 Oct 9.

PMID:
30302753
14.

Tape Stripped Stratum Corneum Samples Prove to be Suitable for Comprehensive Proteomic Investigation of Actinic Keratosis.

Azimi A, Ali M, Kaufman KL, Mann GJ, Fernandez-Penas P.

Proteomics Clin Appl. 2019 May;13(3):e1800084. doi: 10.1002/prca.201800084. Epub 2018 Oct 8.

PMID:
30247810
15.

Advantages of whole-genome sequencing for identification of tumor etiology and clinically actionable genomic aberrations: lessons from the Australian Melanoma Genome Project.

Wilmott JS, Hayward NK, Mann GJ, Scolyer RA.

Melanoma Manag. 2017 Sep;4(3):147-149. doi: 10.2217/mmt-2017-0008. Epub 2017 Jul 26. No abstract available.

16.

Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility.

Wilmott JS, Johansson PA, Newell F, Waddell N, Ferguson P, Quek C, Patch AM, Nones K, Shang P, Pritchard AL, Kazakoff S, Holmes O, Leonard C, Wood S, Xu Q, Saw RPM, Spillane AJ, Stretch JR, Shannon KF, Kefford RF, Menzies AM, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Scolyer RA.

Int J Cancer. 2019 Mar 1;144(5):1049-1060. doi: 10.1002/ijc.31791. Epub 2018 Nov 21.

PMID:
30178487
17.

Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.

Krisp C, Parker R, Pascovici D, Hayward NK, Wilmott JS, Thompson JF, Mann GJ, Long GV, Scolyer RA, Molloy MP.

Br J Cancer. 2018 Sep;119(6):713-723. doi: 10.1038/s41416-018-0227-2. Epub 2018 Aug 17.

18.

Sunscreen Use and Melanoma Risk Among Young Australian Adults.

Watts CG, Drummond M, Goumas C, Schmid H, Armstrong BK, Aitken JF, Jenkins MA, Giles GG, Hopper JL, Mann GJ, Cust AE.

JAMA Dermatol. 2018 Sep 1;154(9):1001-1009. doi: 10.1001/jamadermatol.2018.1774.

19.

Assessing the Incremental Contribution of Common Genomic Variants to Melanoma Risk Prediction in Two Population-Based Studies.

Cust AE, Drummond M, Kanetsky PA; Australian Melanoma Family Study Investigators; Leeds Case-Control Study Investigators, Goldstein AM, Barrett JH, MacGregor S, Law MH, Iles MM, Bui M, Hopper JL, Brossard M, Demenais F, Taylor JC, Hoggart C, Brown KM, Landi MT, Newton-Bishop JA, Mann GJ, Bishop DT.

J Invest Dermatol. 2018 Dec;138(12):2617-2624. doi: 10.1016/j.jid.2018.05.023. Epub 2018 Jun 8.

20.

The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors.

Smit AK, Newson AJ, Morton RL, Kimlin M, Keogh L, Law MH, Kirk J, Dobbinson S, Kanetsky PA, Fenton G, Allen M, Butow P, Dunlop K, Trevena L, Lo S, Savard J, Dawkins H, Wordsworth S, Jenkins M, Mann GJ, Cust AE.

Contemp Clin Trials. 2018 Jul;70:106-116. doi: 10.1016/j.cct.2018.05.014. Epub 2018 May 23.

PMID:
29802966
21.

Telomere sequence content can be used to determine ALT activity in tumours.

Lee M, Teber ET, Holmes O, Nones K, Patch AM, Dagg RA, Lau LMS, Lee JH, Napier CE, Arthur JW, Grimmond SM, Hayward NK, Johansson PA, Mann GJ, Scolyer RA, Wilmott JS, Reddel RR, Pearson JV, Waddell N, Pickett HA.

Nucleic Acids Res. 2018 Jun 1;46(10):4903-4918. doi: 10.1093/nar/gky297.

22.

Rare Variant, Gene-Based Association Study of Hereditary Melanoma Using Whole-Exome Sequencing.

Artomov M, Stratigos AJ, Kim I, Kumar R, Lauss M, Reddy BY, Miao B, Daniela Robles-Espinoza C, Sankar A, Njauw CN, Shannon K, Gragoudas ES, Marie Lane A, Iyer V, Newton-Bishop JA, Timothy Bishop D, Holland EA, Mann GJ, Singh T, Daly MJ, Tsao H.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx083.

23.

Polyunsaturated fatty acids and risk of melanoma: A Mendelian randomisation analysis.

Liyanage UE, Law MH, Ong JS, Cust AE, Mann GJ, Ward SV; Melanoma Meta-Analysis Consortium, Gharahkhani P, Iles MM, MacGregor S.

Int J Cancer. 2018 Aug 1;143(3):508-514. doi: 10.1002/ijc.31334. Epub 2018 Mar 5.

24.

A National Budget Impact Analysis of a Specialised Surveillance Programme for Individuals at Very High Risk of Melanoma in Australia.

Watts CG, Wortley S, Norris S, Menzies SW, Guitera P, Askie L, Mann GJ, Morton RL, Cust AE.

Appl Health Econ Health Policy. 2018 Apr;16(2):235-242. doi: 10.1007/s40258-017-0368-0.

PMID:
29305821
25.

A 14-Protein Signature for Rapid Identification of Poor Prognosis Stage III Metastatic Melanoma.

Sykes EK, McDonald CE, Ghazanfar S, Mactier S, Thompson JF, Scolyer RA, Yang JY, Mann GJ, Christopherson RI.

Proteomics Clin Appl. 2018 May;12(3):e1700094. doi: 10.1002/prca.201700094. Epub 2018 Jan 19.

PMID:
29227041
26.

Sensitivity of Preference-Based Quality-of-Life Measures for Economic Evaluations in Early-Stage Melanoma.

Dieng M, Kasparian NA, Cust AE, Costa DSJ, Tran A, Butow PN, Menzies SW, Mann GJ, Morton RL.

JAMA Dermatol. 2018 Jan 1;154(1):52-59. doi: 10.1001/jamadermatol.2017.4701.

27.

Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families.

Taylor NJ, Mitra N, Goldstein AM, Tucker MA, Avril MF, Azizi E, Bergman W, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon-Albright LA, Cuellar F, Cust AE, Demenais F, Elder DE, Gerdes AM, Ghiorzo P, Grazziotin TC, Hansson J, Harland M, Hayward NK, Hocevar M, Höiom V, Ingvar C, Landi MT, Landman G, Larre-Borges A, Leachman SA, Mann GJ, Nagore E, Olsson H, Palmer JM, Perić B, Pjanova D, Pritchard A, Puig S, van der Stoep N, Wadt KAW, Whitaker L, Yang XR, Newton Bishop JA, Gruis NA, Kanetsky PA; GenoMEL Study Group.

J Invest Dermatol. 2017 Dec;137(12):2606-2612. doi: 10.1016/j.jid.2017.07.829. Epub 2017 Aug 19.

28.

Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center.

Varey AHR, Goumas C, Hong AM, Mann GJ, Fogarty GB, Stretch JR, Saw RPM, Spillane AJ, Shannon KF, Lee KJ, Quinn MJ, Thompson JF, Scolyer RA.

Mod Pathol. 2017 Nov;30(11):1538-1550. doi: 10.1038/modpathol.2017.76. Epub 2017 Jul 21.

29.

Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma.

Jouenne F, Chauvot de Beauchene I, Bollaert E, Avril MF, Caron O, Ingster O, Lecesne A, Benusiglio P, Terrier P, Caumette V, Pissaloux D, de la Fouchardière A, Cabaret O, N'Diaye B, Velghe A, Bougeard G, Mann GJ, Koscielny S, Barrett JH, Harland M, Newton-Bishop J, Gruis N, Van Doorn R, Gauthier-Villars M, Pierron G, Stoppa-Lyonnet D, Coupier I, Guimbaud R, Delnatte C, Scoazec JY, Eggermont AM, Feunteun J, Tchertanov L, Demoulin JB, Frebourg T, Bressac-de Paillerets B.

J Med Genet. 2017 Sep;54(9):607-612. doi: 10.1136/jmedgenet-2016-104402. Epub 2017 Jun 7.

30.

Poor Adherence to National Clinical Management Guidelines: A Population-Based, Cross-Sectional Study of the Surgical Management of Melanoma in New South Wales, Australia.

Varey AHR, Madronio CM, Cust AE, Goumas C, Mann GJ, Armstrong BK, Scolyer RA, Curtin AM, Thompson JF.

Ann Surg Oncol. 2017 Aug;24(8):2080-2088. doi: 10.1245/s10434-017-5890-7. Epub 2017 May 25.

PMID:
28547563
31.

Whole-genome landscapes of major melanoma subtypes.

Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, Patch AM, Kakavand H, Alexandrov LB, Burke H, Jakrot V, Kazakoff S, Holmes O, Leonard C, Sabarinathan R, Mularoni L, Wood S, Xu Q, Waddell N, Tembe V, Pupo GM, De Paoli-Iseppi R, Vilain RE, Shang P, Lau LMS, Dagg RA, Schramm SJ, Pritchard A, Dutton-Regester K, Newell F, Fitzgerald A, Shang CA, Grimmond SM, Pickett HA, Yang JY, Stretch JR, Behren A, Kefford RF, Hersey P, Long GV, Cebon J, Shackleton M, Spillane AJ, Saw RPM, López-Bigas N, Pearson JV, Thompson JF, Scolyer RA, Mann GJ.

Nature. 2017 May 11;545(7653):175-180. doi: 10.1038/nature22071. Epub 2017 May 3.

PMID:
28467829
32.

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H.

Ann Oncol. 2017 May 1;28(5):1130-1136. doi: 10.1093/annonc/mdx026.

PMID:
28327969
33.

Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas.

Rawson RV, Johansson PA, Hayward NK, Waddell N, Patch AM, Lo S, Pearson JV, Thompson JF, Mann GJ, Scolyer RA, Wilmott JS.

Lab Invest. 2017 Feb;97(2):130-145. doi: 10.1038/labinvest.2016.143. Epub 2017 Jan 9.

34.

Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma.

Watts CG, Cust AE, Menzies SW, Mann GJ, Morton RL.

J Clin Oncol. 2017 Jan;35(1):63-71. Epub 2016 Oct 28.

PMID:
28034073
35.

Mutation load in melanoma is affected by MC1R genotype.

Johansson PA, Pritchard AL, Patch AM, Wilmott JS, Pearson JV, Waddell N, Scolyer RA, Mann GJ, Hayward NK.

Pigment Cell Melanoma Res. 2017 Mar;30(2):255-258. doi: 10.1111/pcmr.12571. Epub 2017 Mar 7.

PMID:
28024115
36.

Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial.

Dieng M, Butow PN, Costa DS, Morton RL, Menzies SW, Mireskandari S, Tesson S, Mann GJ, Cust AE, Kasparian NA.

J Clin Oncol. 2016 Dec 20;34(36):4405-4414. Epub 2016 Oct 28.

PMID:
27998215
37.

Protocol for a within-trial economic evaluation of a psychoeducational intervention tailored to people at high risk of developing a second or subsequent melanoma.

Dieng M, Cust AE, Kasparian NA, Butow P, Costa DS, Menzies SW, Mann GJ, Morton RL.

BMJ Open. 2016 Oct 6;6(10):e012153. doi: 10.1136/bmjopen-2016-012153.

38.

A multi-step classifier addressing cohort heterogeneity improves performance of prognostic biomarkers in three cancer types.

Patrick E, Schramm SJ, Ormerod JT, Scolyer RA, Mann GJ, Mueller S, Yang JY.

Oncotarget. 2017 Jan 10;8(2):2807-2815. doi: 10.18632/oncotarget.13203.

39.

Clinical Features Associated With Individuals at Higher Risk of Melanoma: A Population-Based Study.

Watts CG, Madronio C, Morton RL, Goumas C, Armstrong BK, Curtin A, Menzies SW, Mann GJ, Thompson JF, Cust AE.

JAMA Dermatol. 2017 Jan 1;153(1):23-29. doi: 10.1001/jamadermatol.2016.3327.

PMID:
27829101
40.

"Melanoma: Questions and Answers." Development and evaluation of a psycho-educational resource for people with a history of melanoma.

Kasparian NA, Mireskandari S, Butow PN, Dieng M, Cust AE, Meiser B, Barlow-Stewart K, Menzies S, Mann GJ.

Support Care Cancer. 2016 Dec;24(12):4849-4859. Epub 2016 Jul 27.

PMID:
27465047
41.

A Pilot Randomized Controlled Trial of the Feasibility, Acceptability, and Impact of Giving Information on Personalized Genomic Risk of Melanoma to the Public.

Smit AK, Espinoza D, Newson AJ, Morton RL, Fenton G, Freeman L, Dunlop K, Butow PN, Law MH, Kimlin MG, Keogh LA, Dobbinson SJ, Kirk J, Kanetsky PA, Mann GJ, Cust AE.

Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):212-221. doi: 10.1158/1055-9965.EPI-16-0395. Epub 2016 Oct 4.

42.

Doctors' recognition and management of melanoma patients' risk: An Australian population-based study.

Madronio CM, Armstrong BK, Watts CG, Goumas C, Morton RL, Curtin A, Menzies SW, Mann GJ, Thompson JF, Cust AE.

Cancer Epidemiol. 2016 Dec;45:32-39. doi: 10.1016/j.canep.2016.09.006. Epub 2016 Sep 28.

PMID:
27689254
43.

Diagnosis and clinical management of melanoma patients at higher risk of a new primary melanoma: A population-based study in New South Wales, Australia.

Watts CG, Madronio CM, Morton RL, Goumas C, Armstrong BK, Curtin A, Menzies SW, Mann GJ, Thompson JF, Cust AE.

Australas J Dermatol. 2017 Nov;58(4):278-285. doi: 10.1111/ajd.12530. Epub 2016 Aug 1.

PMID:
27477217
44.

Development and External Validation of a Melanoma Risk Prediction Model Based on Self-assessed Risk Factors.

Vuong K, Armstrong BK, Weiderpass E, Lund E, Adami HO, Veierod MB, Barrett JH, Davies JR, Bishop DT, Whiteman DC, Olsen CM, Hopper JL, Mann GJ, Cust AE, McGeechan K; Australian Melanoma Family Study Investigators.

JAMA Dermatol. 2016 Aug 1;152(8):889-96. doi: 10.1001/jamadermatol.2016.0939.

45.

Differential distribution improves gene selection stability and has competitive classification performance for patient survival.

Strbenac D, Mann GJ, Yang JY, Ormerod JT.

Nucleic Acids Res. 2016 Jul 27;44(13):e119. doi: 10.1093/nar/gkw444. Epub 2016 May 17.

46.

Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making.

De Paoli-Iseppi R, Johansson PA, Menzies AM, Dias KR, Pupo GM, Kakavand H, Wilmott JS, Mann GJ, Hayward NK, Dinger ME, Long GV, Scolyer RA.

Pathology. 2016 Apr;48(3):261-6. doi: 10.1016/j.pathol.2016.01.001. Epub 2016 Mar 9.

PMID:
27020503
47.

The molecular profile of metastatic melanoma in Australia.

Lyle M, Haydu LE, Menzies AM, Thompson JF, Saw RP, Spillane AJ, Kefford RF, Mann GJ, Cooper WA, Yu B, Scolyer RA, O'Toole SA, Long GV.

Pathology. 2016 Feb;48(2):188-93. doi: 10.1016/j.pathol.2015.12.008. Epub 2016 Jan 18.

PMID:
27020391
48.

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.

Madore J, Strbenac D, Vilain R, Menzies AM, Yang JY, Thompson JF, Long GV, Mann GJ, Scolyer RA, Wilmott JS.

Clin Cancer Res. 2016 Aug 1;22(15):3915-23. doi: 10.1158/1078-0432.CCR-15-1714. Epub 2016 Mar 9.

49.

Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.

Taylor NJ, Handorf EA, Mitra N, Avril MF, Azizi E, Bergman W, Bianchi-Scarrà G, Bishop DT, Bressac-de Paillerets B, Calista D, Cannon-Albright LA, Cuellar F, Cust AE, Demenais F, Elder DE, Friedman E, Gerdes AM, Ghiorzo P, Goldstein AM, Grazziotin TC, Hansson J, Hayward NK, Hocevar M, Höiom V, Holland EA, Ingvar C, Landi MT, Landman G, Larre-Borges A, Leachman SA, Mann GJ, Nagore E, Olsson H, Palmer J, Perić B, Pjanova D, Puig S, Schmid H, van der Stoep N, Tucker MA, Wadt KAW, Whitaker L, Yang XR, Newton Bishop JA, Gruis NA, Kanetsky PA; GenoMEL Consortium.

J Invest Dermatol. 2016 May;136(5):1066-1069. doi: 10.1016/j.jid.2016.01.009. Epub 2016 Jan 28. No abstract available.

50.

Economic evaluations of psychosocial interventions in cancer: a systematic review.

Dieng M, Cust AE, Kasparian NA, Mann GJ, Morton RL.

Psychooncology. 2016 Dec;25(12):1380-1392. doi: 10.1002/pon.4075. Epub 2016 Jan 26. Review.

PMID:
26810383

Supplemental Content

Support Center